Listed

Cellectar Biosciences, Inc.

CLRBNasdaqCIK 1279704HealthcareFiscal year ends Dec 31

Reports and events: 532 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Cellectar Biosciences, Inc., Reports and events
FiledFormWhat it isAccession number
2024-07-2306:45 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-24-081680
2024-07-2206:45 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-24-081307
2024-07-1117:15 ET8-K4.01 Change of auditor; 9.01 Financial statements and exhibits0001104659-24-079262
2024-06-2516:09 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation0001104659-24-074747
2024-06-1417:04 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-24-071822
2024-05-1406:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-24-060865
2024-05-1406:32 ET10-QQuarterly reportPeriod 2024-03-310001410578-24-000771
2024-04-2616:58 ETDEF 14AProxy statementPeriod 2024-06-140001104659-24-053057
2024-04-0117:00 ET10-K/AAnnual report, amendedPeriod 2023-12-310001104659-24-041930
2024-03-2706:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-24-039341
2024-03-2706:30 ET10-KAnnual reportPeriod 2023-12-310001410578-24-000307
2024-02-0206:03 ET8-K8.01 Other events0001104659-24-009664
2024-01-2516:30 ET8-K8.01 Other events0001104659-24-006709
2024-01-0906:02 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-24-002401
2023-11-2916:31 ET8-K8.01 Other events0001104659-23-122057
2023-11-1306:30 ET10-QQuarterly reportPeriod 2023-09-300001410578-23-002341
2023-11-0207:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-23-113593
2023-10-2716:40 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-23-112202
2023-10-0216:40 ETDEF 14AProxy statementPeriod 2023-10-250001104659-23-105926
2023-09-0817:17 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001104659-23-099368
2023-08-2116:30 ET8-K3.01 Delisting notice0001104659-23-093947
2023-08-1408:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-23-091006
2023-08-1408:30 ET10-QQuarterly reportPeriod 2023-06-300001410578-23-001833
2023-06-2916:31 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-23-076346
2023-06-2906:03 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-23-075997
2023-06-2006:08 ET8-K/A8.01 Other events0001104659-23-072483
2023-06-1416:25 ET8-K8.01 Other events0001104659-23-071211
2023-06-1316:30 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-23-070826
2023-05-0408:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-23-055815
2023-05-0408:31 ET10-QQuarterly reportPeriod 2023-03-310001410578-23-000875
2023-04-2816:15 ETDEF 14AProxy statementPeriod 2023-06-140001104659-23-052980
2023-03-1616:36 ET10-K/AAnnual report, amendedPeriod 2022-12-310001104659-23-033350
2023-03-0908:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-23-030354
2023-03-0908:35 ET10-KAnnual reportPeriod 2022-12-310001410578-23-000224
2023-01-0407:00 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation0001104659-23-000616
2022-12-0217:23 ET8-K1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001104659-22-124193
2022-11-2316:20 ETS-1Registration statement0001104659-22-121762
2022-11-0308:45 ET10-QQuarterly reportPeriod 2022-09-300001410578-22-002920
2022-11-0308:40 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-22-114234
2022-10-2517:03 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-22-111217
2022-09-2208:45 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-22-102181
2022-09-1308:45 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-22-099483
2022-08-0508:46 ET10-QQuarterly reportPeriod 2022-06-300001410578-22-002052
2022-08-0508:40 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-22-086472
2022-07-2116:30 ET8-K5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-22-081598
2022-06-2716:30 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-22-074774
2022-06-0719:18 ET8-K8.01 Other events0001104659-22-068653
2022-05-1008:45 ET10-QQuarterly reportPeriod 2022-03-310001410578-22-001231
2022-05-1008:41 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-22-057982
2022-05-0616:01 ET8-K3.01 Delisting notice0001104659-22-056977

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 16:55 ET. Listed shows no prices and gives no investment advice.